

Please type a plus sign (+) inside this box



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center"><i>(use as many sheets as necessary)</i></p>		Complete if Known			
		Application Number	10/016,969		
		Filing Date	Dec 14, 2001		
		First Named Inventor	Pittner, R.A.		
		Art Unit	1646		
		Examiner Name	Ruixiang, Li		
Sheet		of		Attorney Docket Number	24001-010

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Publication Date MMDDYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ .Kind Code ⁵ (if known)				
RLi	AA	WO	00/47219	08-17-2000	Ontogeny, Inc.		


RECEIVED
JUL 24 2002
TECH CENTER 1600/2900

Examiner Signature	<i>Ruixiang L</i>	Date Considered	8/12/2002
-----------------------	-------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number(optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



PTO/SB/08A (08-2002)

Approved for use through 10/31/2002. OMB 0651-0047

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A1PT0

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	Pittner, et al.
Group Art Unit	1614-1646
Examiner Name	Not Yet Assigned Ruixiang Li
Attorney Docket Number	240010-010

Sheet

5

5


RLi	✓	STANLEY B. G., et al. "Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion." <u>Peptides</u> 6: 1205-11, 1985	
	✓	SURWIT R. S., et al. "Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice." <u>Metabolism - Clinical and Experimental</u> 44:645-651, 1995	
	✓	TANIGUCHI H., et al. "Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo." <u>Eur J Pharmacol</u> 312: 227-33, 1996	
	✓	TATEMOTO K. "Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion." <u>Proc Natl Acad Sci U S A</u> 79: 2514-8, 1982	
	✓	TATEMOTO K. "Neuropeptide Y: complete amino acid sequence of the brain peptide." <u>Proc Natl Acad Sci U S A</u> 79: 5485-9, 1982	
	✓	TATEMOTO K., et al. "Neuropeptide Y a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide." <u>Nature</u> 296: 659-60, 1982	
	✓	UENO N., et al. "Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice." <u>Gastroenterology</u> 117: 1427-32, 1999	
	✓	YANG H., et al. "PYY-preferring receptor in the dorsal vagal complex and its involvement in PYY stimulation of gastric acid secretion in rats." <u>Br J Pharmacol</u> 123: 1549-54, 1998	
	✓	YANG H., et al. "PYY in brain stem nuclei induces vagal stimulation of gastric acid secretion in rats." <u>Am J Physiol</u> 268: G943-8, 1995	
	✓	YOSHINAGA K., et al. "Structural requirements of peptide YY for biological activity at enteric sites." <u>Am J Physiol</u> 263:G695-701, 1992	
	✓	YOUNG A., et al. "Genetically obese (ob/ob) mice are more sensitive to amylin and endotoxin-induced suppression of food intake." <u>Program and Abstracts, 10th International Congress of Endocrinology</u> 419 (poster P2-58), 1996	
	✓	KUSHI, et al., "Obesity and mild hyperinsulinemia found in Neuropeptide Y-Y1 receptor-deficient mice." <u>Proc. Natl. Acad. Sci. USA</u> Vol. 95, pp. 15659-15664, December 1998	
	✓	ALLEN, et al., "Effects of Peptide YY and Neuropeptide Y on Gastric Emptying in Man." <u>Digestion</u> 30:255-262, 1984	

Examiner Signature	<i>Ruixiang Li</i>	Date Considered	8/12/2002
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a (+) sign inside this box ☐

PTO/SB/08A (08-06)

Approved for use through 10/31/2002. OMB 0651-0037
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A1PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	Pittner, et al.
Group Art Unit	1614 1646
Examiner Name	Not Yet Assigned Ruixiang Li
Attorney Docket Number	240010-010

RLi	✓	KIMMEL J. R., et al. "Isolation and characterization of chicken insulin." <u>Endocrinology</u> 83: 1323-30, 1968	
	✓	KOPELMAN P. G. "Obesity as a medical problem." <u>Nature</u> 404: 635-43, 2000	
	✓	LLOYD K. C. K., et al. "Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y-1 receptors." <u>Am J Physiol</u> 270:G123-G127, 1996	
	✓	MALAISSÉ-LAGAE F., et al. "Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse." <u>Hypothesis. Experientia</u> 33: 915-7, 1977	
	✓	MARSH D. J., et al. "Role of the Y5 neuropeptide Y receptor in feeding and obesity." <u>Nat Med</u> 4:718-21, 1998	
	✓	MICHEL M. C., et al. "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors." <u>Pharmacol Rev</u> 50: 143-50, 1998	
	✓	MORLEY J. E., et al. "Modulation of food intake by peripherally administered amylin." <u>Am J Physiol</u> 267:R178-R184, 1994	
	✓	MORLEY J. E., et al. "Peptide YY (PYY), a potent orexigenic agent." <u>Brain Res</u> 341: 200-203, 1985	
	✓	MUNSON P. J. et al. "Ligand: a versatile computerized approach for characterization of ligand-binding systems." <u>Anal Biochem</u> 107: 220-39, 1980	
	✓	NAKAJIMA M., et al. "Effects of pancreatic polypeptide family peptides on feeding and learning behavior in mice." <u>J Pharmacol Exp Ther</u> 268:1010-4, 1994	
	✓	PAPPAS T. N., et al. "Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs." <u>Gastroenterology</u> 91:1386-9, 1986	
	✓	PAPPAS T. N., et al. "Peptide YY inhibits meal-stimulated pancreatic and gastric secretion." <u>Am J Physiol</u> 248:G118-23, 1985	
	✓	PELLEYMOUNTER M. A., et al. "Effects of the obese gene product on body weight regulation in ob/ob mice." <u>Science</u> 269:540-543, 1995	
	✓	RISSANEN A., et al. "Risk of disability and mortality due to overweight in a Finnish population." <u>BMJ</u> 301: 835-7, 1990	
	✓	SAVAGE A. P., et al. "Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers." <u>Gut</u> 28:166-70, 1987	
	✓	SCATCHARD G. "The attraction of proteins for small molecules and ions." <u>Ann NY Acad Sci</u> 51: 660, 1949	
	✓	SCHWARTZ M. W., et al. "Central nervous system control of food intake." <u>Nature</u> 404: 661-71, 2000	

Examiner Signature	Ruixiang Li	Date Considered	8/12/02
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (08-

Approved for use through 10/31/2002. OMB 0651-0001

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A1PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	Pittner, et al.
Group Art Unit	1614 1646
Examiner Name	Not Yet Assigned Ruixiang Li
Attorney Docket Number	240010-010

Sheet	3	5
-------	---	---

RLi	✓	Dis Sci 46:156-65, 2001
	✓	EBERLEIN G. A., et al. "A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36)." <u>Peptides</u> 10:797-803, 1989
	✓	GEDULIN B., et al. "Assessment of gastric emptying from appearance in plasma of 3H from gavaged [3-3H] glucose in conscious rats: effects of amylin." <u>Gastroenterology</u> 108:A604, 1995
	✓	GEHLERT D. R. "Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implications." <u>Proc Soc Exp Biol Med</u> 218:7-22, 1998
	✓	GRANDT D., et al. "Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36." <u>Regul Pept</u> 51:151-9, 1994
	✓	GREELEY G. H. Jr., et al. "Inhibition of gastric acid secretion by peptide YY is independent of gastric somatostatin release in the rat." <u>Proc Soc Exp Biol Med</u> 189:325-8, 1988
	✓	GUAN D., et al. "Peptide-YY, a new partner in the negative feedback control of pancreatic secretion." <u>Endocrinology</u> 128:911-6, 1991
	✓	GUE M et al. "Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats." <u>Br J Pharmacol</u> 118:237-42, 1996
	✓	HALAAS J. L., et al. "Weight-reducing effects of the plasma protein encoded by the obese gene." <u>Science</u> 269:543-6, 1995
	✓	HAYNES J. M., et al. "Neuropeptide Y (NPY) and peptide YY (PYY) effects in the epididymis of the guinea-pig: evidence of a pre-junctional PYY-selective receptor." <u>Br J Pharmacol</u> 122:1530-6, 1997
	✓	HOENTJEN F., et al. "Role of circulating peptide YY in the inhibition of gastric acid secretion by dietary fat in humans." <u>Scand J Gastroenterol</u> 35:166-71, 2000
	✓	IYENGAR S., et al. "Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?" <u>J Pharmacol Exp Ther</u> 289:1031-40, 1999
	✓	KANATANI A., et al. "Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice." <u>Endocrinology</u> 141:1011-6, 2000
	✓	KATO K., et al. "CGRP antagonists enhance gastric acid secretion in 2-h pylorus-ligated rats." <u>Peptides</u> 16:1257-1262, 1995
	✓	KAWAKUBO K., et al. "Intracisternal PYY inhibits gastric lesions induced by ethanol in rats: role of PYY-preferring receptors?" <u>Brain Res</u> 854:30-4, 2000

Examiner Signature	Ruixiang Li	Date Considered	8/12/2002
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 1 5 2002

RECEIVED

TECH CENTER 1001/2900



Please type a plus (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A1PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	Pittner, et al.
Group Art Unit	1614 1646
Examiner Name	Not Yet Assigned Ruixiang
Attorney Docket Number	240010-010

Sheet

2

5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	✓	ADRIAN T. E., et al. "Human distribution and release of a putative new gut hormone, peptide YY." <u>Gastroenterology</u> 89:1070-7, 1985	
	✓	ASAKAWA A., et al. "Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice." <u>Peptides</u> 20: 1445-8, 1999	
	✓	BALASUBRAMANIAM A., et al. "Structure-activity studies including a $\Psi(\text{CH}_2\text{-NH})$ scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine." <u>J Med Chem</u> 43:3420-7, 2000	
	✓	BONAZ B., et al. "Peripheral peptide YY induces c-fos-like immunoreactivity in the rat brain." <u>Neurosci Lett</u> 163:77-80, 1993	
	✓	BROWN K. K., et al. "A Novel N-Aryl Tyrosine Activator of Peroxisome Proliferator-Activated Receptor-Gamma Reverses the Diabetic Phenotype of the Zucker Diabetic Fatty Rat." <u>Diabetes</u> 48: 1415-24, 1999	
	✓	CAMPFIELD L. A., et al. "Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks." <u>Science</u> 269:546-549, 1995	
	✓	CHEN C. H., et al. "Central inhibitory action of peptide YY on gastric motility in rats." <u>Am J Physiol</u> 269: R787-R792, 1995	
	✓	CHEN C. H., et al. "Intracisternal injection of peptide YY inhibits gastric emptying in rats." <u>Regul Pept</u> 61:95-98, 1996	
	✓	CHEN C. H., et al. "PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC." <u>Neurogastroenterol Motil</u> 9:109-116, 1997	
	✓	CLARK J. T., et al. "Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats." <u>Endocrinology</u> 115:427-9, 1984	
	✓	CLARK J. T., et al. "Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY." <u>Regul Pept</u> 17:31-9, 1987	
	✓	CORP E. S., et al. "Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors." <u>Am J Physiol</u> 259:R317-23, 1990	
	✓	DENG X., et al. "PYY potently inhibits pancreatic exocrine secretion mediated through CCK-secretin-stimulated pathways but not 2-DG-stimulated pathways in awake rats." <u>Dig</u>	

Examiner
Signature

Ruixiang L.

Date
Considered

8/12/2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 1 5 2002

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box



PTO/SB/08A (08-09)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A1PT0

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	Pittner, et al.
Group Art Unit	1614 1646
Examiner Name	Not Yet Assigned Ruixiang Li
Attorney Docket Number	24001-010

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No ¹	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Rhi		4,891,357		01-02-1990	Kala	
		5,604,203		02-18-1997	Balasubramaniam	
		5,912,227		06-15-1999	Croom, Jr. et al.	
		5,939,462		08-17-1999	Connell et al.	
		5,968,819		10-19-1999	Gerald et al.	
		6,013,622		01-11-2000	Bruno et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature	Ruixiang Li	Date Considered	8/12/2002
-----------------------	-------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number(optional). ² See attached Kinds of U.S. Patent Documents, at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 15 2002

RECEIVED

TECH CENTER 1600/2900